Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Malignant Peripheral Nerve Sheath Tumor, Locally Advanced Myxofibrosarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Angiosarcoma, Metastatic Epithelioid Sarcoma, Metastatic Fibrosarcoma, Metastatic Liposarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Myxofibrosarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Undifferentiated (Embryonal) Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Unresectable Soft Tissue Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Conditions
Brief summary
This phase Ib trial studies the side effects and best dose of ribociclib when giving together with doxorubicin hydrochloride in treating patients with soft tissue sarcomas that has spread to other places or that cannot be removed by surgery (advanced). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib and doxorubicin hydrochloride may work better in treating patients with soft tissue sarcoma.
Detailed description
PRIMARY OBJECTIVE: I. To determine the recommended phase 2 dose (RP2D) of ribociclib in combination with doxorubicin in subjects with advanced soft tissue sarcomas. SECONDARY OBJECTIVES: I. To assess preliminary anti-tumor activity of ribociclib in combination with doxorubicin in subjects with advanced soft tissue sarcomas. II. To characterize the safety and tolerability of ribociclib in combination with doxorubicin. OUTLINE: This is a dose-escalation study of ribociclib. Patients receive ribociclib orally (PO) daily on days 1-7, and doxorubicin hydrochloride intravenously (IV) on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients without disease progression after 6 cycles receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up within 30 days and then every 12 weeks for 12 months.
Interventions
Given IV
Correlative studies
Correlative studies
Given PO
Sponsors
Study design
Eligibility
Inclusion criteria
* Pathologically confirmed diagnosis of intermediate or high-grade soft tissue sarcoma for which single-agent doxorubicin is appropriate therapy, including but not limited to: * Synovial sarcoma * Fibrosarcoma * Undifferentiated sarcoma * Liposarcoma * Leiomyosarcoma * Angiosarcoma * Malignant peripheral nerve sheath tumor * Pleomorphic rhabdomyosarcoma * Myxofibrosarcoma * Epithelioid sarcoma * Undifferentiated pleomorphic sarcoma * Locally advanced unresectable or metastatic disease with no standard curative therapy available * Archival tumor tissue retinoblastoma-associated protein (pRb) positive by immunohistochemistry (IHC) * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria * All races and ethnic groups will be included; for subjects between the ages of 12-18 years only, body surface area (BSA) must be \>= 1.28 m\^2 * Ejection fraction of \>= 50% by echocardiogram or multi-gated acquisition (MUGA) scan * Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening and within 14 days prior to planned first dose of ribociclib * Willing to use adequate contraception throughout the study and for 3 weeks after study drug discontinuation * Meets the following standard 12-lead electrocardiography (ECG) parameters at screening (defined as the mean of the triplicate ECGs; ECGs done in triplicate do not have a defined interval between assessments): * Corrected QT using Fridericia's correction formula (QTcF) interval at screening \< 450 msec for males and \< 470 msec for females (using Fridericia's correction) * Resting heart rate =\< 100 beats per minute (bpm) * Absolute neutrophil count (ANC) \>= 1.5 K/cu mm * Platelets (no transfusion within prior 7 days) \>= 100 K/cu mm * Hemoglobin (no transfusion within prior 7 days) \>= 9.0 g/dL * Total bilirubin \< institutional upper limit of normal (ULN), except for subjects with documented Gilbert's syndrome, for which =\< 3.0 x ULN or direct bilirubin =\< 1.5 x ULN * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT) in the absence of liver metastases: =\< 2.5 x ULN; if the subject has liver metastases: \< 5 x ULN * Serum creatinine \< 1.7 mg/dL * Potassium within institutional normal limit (WNL) * Corrected calcium WNL * Magnesium WNL * International normalized ratio (INR) =\< 1.5 * Use of rivaroxaban, apixaban, edoxaban or warfarin is an
Exclusion criteria
; therapy with heparin, low molecular weight heparin (LMWH), dabigatran or fondaparinux is allowed * All prior treatment-related toxicities resolved to =\< grade 1 or are determined to be clinically stable by the investigator * Has completed prior therapies according to the criteria below: * Cytotoxic chemotherapy - at least 21 days since last dose prior to first dose of ribociclib * Small molecule inhibitors - at least 14 days since last dose prior to first dose of ribociclib * Monoclonal antibodies - at least 3 half-lives since last dose prior to first dose of ribociclib; exception: denosumab for bony metastases is allowable * Immunotherapy (e.g. tumor vaccines) - at least 42 days since last dose prior to first dose of ribociclib * Radiation - at least 14 days since last dose prior to first dose of ribociclib * Able to swallow capsules * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Life expectancy \> 3 months * Ability to understand and the willingness to sign a written informed consent document; subject has signed the informed consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of dose limiting toxicities (DLTs) of adverse events | Up to 21 days | Will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03. All adverse events (AEs) will be tabulated and summarized by major organ category, grade, anticipation, and drug attribution. Serious adverse events (SAE) specific incidence and exact 95% confidence interval will be provided where appropriate. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | From first dose of protocol therapy to time of documented radiographic and/or clinical disease progression or death from any cause, whichever occurs first, assessed up to 12 months | The Kaplan-Meier product limit method will be used to estimate PFS of the median PFS and PFS rates at clinically relevant time points will be provided with the 90% confidence interval (CI). |
| Objective response rate (ORR) | Up to 12 months | Will be defined as the proportion of patients who achieved a complete response or a partial response. Will be assessed based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1. The ORR, along with exact two-sided 95% confidence intervals, will be reported for the study. |
| Incidence of adverse events, SAEs | Up to 12 months | Will be assessed by NCI CTCAE v 4.03. Analyses will be performed for all patients having received at least one dose of study drug. Serious adverse events, AEs will be summarized using descriptive statistics. |
| Incidence of dose modifications (interruptions, reductions, intensity) due to adverse events | Up to 12 months | Analyses will be performed for all patients having received at least one dose of study drug. AEs leading to withdrawal/dose interruptions/dose modification will be summarized using descriptive statistics. |
Countries
United States